贝达喹啉与德拉马尼联合治疗耐药结核病患者在亚美尼亚、印度和南非的早期安全性与有效性:回顾性队列研究
该回顾性队列研究分析了亚美尼亚、印度和南非无国界医生支持项目中28例接受贝达喹啉与德拉马尼联合方案6-12个月的耐药结核病患者,未发现QTcF间期增加超过500 ms者,23例基线培养阳性者中17例(74%)在治疗6个月时培养转阴,作者认为联合方案未显示叠加或协同的QTcF延长效应。
要点
- 28例患者中无QTcF间期增加超过500 ms者,4例(14%)出现6次QTcF较基线增加超过60 ms。
- 23例基线培养阳性患者中17例(74%)在治疗6个月时培养转阴。
- 作者认为贝达喹啉与德拉马尼联合方案未显示叠加或协同的QTcF延长效应。
核心结论
- 使用贝达喹啉与德拉马尼联合方案似乎未显示叠加或协同的QTcF延长效应。
- 对于治疗选择有限的患者,在等待正式临床试验结果期间,应扩大贝达喹啉与德拉马尼联合方案的可及性。
研究设计与样本
- 回顾性队列研究,纳入2016年1月1日至2016年8月31日在亚美尼亚埃里温、印度孟买和南非卡耶利沙的无国界医生支持项目中所有接受6-12个月口服贝达喹啉与德拉马尼联合方案的患者28例。
- 给药方案为贝达喹啉400 mg每日一次共2周,之后贝达喹啉200 mg每周三次,德拉马尼100 mg每日两次。
- 报告治疗前6个月内的严重不良事件、Fridericia公式校正的QTc(QTcF)间期数据和培养转阴数据。
主要发现
- 28例患者中位年龄32.5岁(IQR 28.5-40.5),17例为男性。
- 28例中11例(39%)HIV阳性;24例(86%)分离株对氟喹诺酮类耐药;14例(50%)为广泛耐药结核病。
- 无患者QTcF间期增加超过500 ms;4例(14%)出现6次QTcF较基线增加超过60 ms,但无一永久停药。
- 7例患者共报告16起严重不良事件。
- 23例基线培养阳性者中,17例(74%)在治疗6个月时培养转阴。
临床怎么用
- 作者认为贝达喹啉与德拉马尼联合方案似乎未显示叠加或协同的QTcF延长效应。
- 作者建议对于治疗选择有限的患者,在等待正式临床试验结果期间应扩大贝达喹啉与德拉马尼联合方案的可及性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa. METHODS: We retrospectively analysed a cohort of all patients who received 6-12 months of oral bedaquiline and delamanid in combination (400 mg bedaquiline once per day for 2 weeks, then 200 mg bedaquiline three times per week and 100 mg delamanid twice per day) in MSF-supported projects. We report serious adverse events, QTc corrected using the Fridericia formula (QTcF) interval data, and culture conversion data during the first 6 months of treatment. FINDINGS: Between Jan 1, 2016, and Aug 31, 2016, 28 patients (median age 32·5 years [IQR 28·5-40·5], 17 men) were included in the analysis. 11 (39%) of 28 patients were HIV-positive. 24 patients (86%) had isolates resistant to fluoroquinolones; 14 patients (50%) had extensively drug-resistant tuberculosis. No patient had an increase of more than 500 ms in their QTcF interval. Four patients (14%) had six instances of QTcF increase of more than 60 ms from baseline but none permanently discontinued the drugs. 16 serious adverse events were reported in seven patients. Of 23 individuals with positive baseline cultures, 17 (74%) converted to negative by month 6 of treatment. INTERPRETATION: Use of the bedaquiline and delamanid combination appears to reveal no additive or synergistic QTcF-prolonging effects. Access to bedaquiline and delamanid in combination should be expanded for people with few treatment options while awaiting the results of formal clinical trials. FUNDING: Médecins Sans Frontières (MSF).
引用
- Ferlazzo G, Mohr E, Laxmeshwar C, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018. PMID: 29452942. doi:10.1016/S1473-3099(18)30100-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。